Following two phase lll clinical trials conducted in the USA/Mexico and in the UK, the Therapeutic Goods Administration (TGA) has granted provisional approval of the Novavvax COVID-19 vaccine in Australia. 

Novavax COVID-19 vaccine, also known as Nuvaxovid (Biocelect Pty Ltd/Novavax Inc) is a spike protein-based vaccine with each 0.5mL dose containing 5 micrograms of the of SARS-CoV-2 spike protein and 50 micrograms of Matrix-M as an adjuvant.

Novavax COVID-19 vaccine demonstrated to be highly effective in preventing symptomatic COVID-19 disease in adults in a primary schedule. ATAGI continues to monitor the safety, efficacy and immunogenicity data of Novavax COVID-19 vaccine including in high-risk priority groups and will provide updated recommendations as required.  

To read the full ATAGI statement, follow the link below:
ATAGI Statement on the use of Novavax COVID-19 vaccine (Nuvaxovid)